García-Cabezas Sonia, Rivin Del Campo Eleonor, Solivera-Vela Juan, Palacios-Eito Amalia
Department of Radiation Oncology, Reina Sofia University Hospital, Cordoba 14004, Spain.
Department of Radiation Oncology, Tenon University Hospital, Paris 75020, France.
World J Clin Oncol. 2021 Sep 24;12(9):767-786. doi: 10.5306/wjco.v12.i9.767.
Optimal management after recurrence or progression of high-grade gliomas is still undefined and remains a challenge for neuro-oncology multidisciplinary teams. Improved radiation therapy techniques, new imaging methods, published experience, and a better radiobiological knowledge of brain tissue have positioned re-irradiation (re-RT) as an option for many of these patients. Decisions must be individualized, taking into account the pattern of relapse, previous treatment, and functional status, as well as the patient's preferences and expected quality of life. Many questions remain unanswered with respect to re-RT: Who is the most appropriate candidate, which dose and fractionation are most effective, how to define the target volume, which imaging technique is best for planning, and what is the optimal timing? This review will focus on describing the most relevant studies that include re-RT as salvage therapy, with the aim of simplifying decision-making and designing the best available therapeutic strategy.
高级别胶质瘤复发或进展后的最佳管理方案仍不明确,对神经肿瘤多学科团队来说仍是一项挑战。改进的放射治疗技术、新的成像方法、已发表的经验以及对脑组织更好的放射生物学认识,已将再程放疗(re-RT)作为许多此类患者的一种选择。决策必须个体化,要考虑复发模式、既往治疗、功能状态以及患者的偏好和预期生活质量。关于再程放疗仍有许多问题未得到解答:谁是最合适的候选人,哪种剂量和分割方式最有效,如何定义靶区体积,哪种成像技术最适合用于计划制定,以及最佳时机是什么?本综述将重点描述将再程放疗作为挽救性治疗的最相关研究,目的是简化决策制定并设计出最佳可用治疗策略。